Early Renal Replacement Therapy in COVID 19 Patients With AKI Does it Improve the Outcome?

Sohag University100 enrolled

Overview

patients will be divided into two equal groups, each group including 50 adult patients with a confirmed diagnosis of covid, patients with acute kidney injury, the first group will be treated with early hemodialysis, second group will be conservative until there is an urgent need for dialysis

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

DOUBLE

Enrollment

100

Conditions

Multi Organ Failure

Interventions

haemodialysisPROCEDURE

continuous venovenous hemodiafiltration (CVVHDF) at a prescribed dose of 30-35 mL/kg/h of effluent and with regional citrate anticoagulation

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * adult patients (≥18 years old) with confirmed severe acute respiratory syndrome coronavirus 2 infections admitted to the ICU. Exclusion Criteria: * •Malignancy. * Immuno-deficiency diseases. * Chronic diabetic, cardiac and hypertensive patients * autoimmune diseases.

Locations (1)

Faculty of Medicine, Sohag University

Sohag, Egypt

Outcomes

Primary Outcomes

reduction of Sequential Organ Failure Assessment Score

prevention of multi-organ failure associated with covid including respiratorym circulatory, liver and renal failure

Time frame: 2 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.